Current Gold Standards for MSI Testing and the Clinical Relevance of the MSI-H Biomarker
In this webinar, you will learn about the:
- Comparison between techniques to measure MSI to current gold-standard methods
- Clinical utility of the MSI biomarker for Lynch syndrome screening and immunotherapy treatment
- Current clinical practice guidelines for MSI testing
Summary
Historically MSI has been used to screen for Lynch syndrome, a dominant hereditary cancer propensity. Since 2015, MSI status has been rediscovered as a biomarker for immunotherapeutic response, making MSI status an increasingly relevant tool for genetics and immuno-oncology applications. In this webinar, we will discuss MSI testing gold standards and compare the different methods that are currently being used for MSI testing for mismatch repair deficient (dMMR) tumors. We will also discuss the clinical relevance of the MSI-H biomarker focusing on the pathological and epidemiological characteristics of MSI-H/dMMR tumors, and the role of MSI testing in Lynch syndrome screening, colorectal cancer patient prognosis, and immunotherapy treatment.
Have Questions? We are here to help!
Our Medical Affairs team is happy to answer any questions you have after watching this webinar. We are a team of scientific experts focused on discovering and communicating medial insights to support the evolution of clinical diagnostic products and technologies. Send us a Medical Affairs inquiry today!